Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

Congo-Kinshasa: U.S. Releases Experimental Ebola Drug for DR Congo Outbreak Trials

The United States has begun shipping experimental Ebola treatments to the Democratic Republic of Congo, where an outbreak has caused more than 1,000 cases and over 250 deaths. The drugs, including MBP134, will be used for compassionate care and clinical trials in the affected region.

By Tertius News AI Desk 2 outlets · 2 articles Version 1 Coverage Jun 24, 2026 Published Aug 14

Experimental Ebola Drugs Shipped to DR Congo as Outbreak Surpasses 1,000 Cases

The United States has begun shipping experimental Ebola treatments to the Democratic Republic of Congo (DRC), where an outbreak has caused more than 1,000 confirmed cases and over 250 deaths, according to the World Health Organization (WHO) and US officials.

The US Department of Health and Human Services confirmed it will provide doses of MBP134, an antibody drug developed by California-based Mapp Biopharmaceutical, for compassionate use in the DRC and to support a clinical trial in the outbreak region. A department spokesperson told Reuters that the drug is being made available for compassionate use in Congo as well as to advance a clinical trial in the outbreak area.

Previously, Washington had said doses of the drug would only be made available to its own citizens considered at high risk after exposure to the virus. The spokesperson added that trial data could help support future regulatory review and possible US approval, but declined to say how many doses were being provided.

The outbreak, caused by the Bundibugyo strain of Ebola, has no approved vaccines or treatments. The DRC has recorded more than 1,000 confirmed cases since the outbreak was confirmed on 15 May. The Africa Centre for Strategic Studies warned that the number of cases has risen faster than in any previous Ebola outbreak on record.

The WHO said shipments of MBP134 and other treatments intended for trials are already on their way. The agency is working with health partners to prepare trial enrolment at treatment facilities in the affected region. Trials of the Mapp drug and two antivirals developed by US pharmaceutical company Gilead Sciences are due to begin in the coming weeks, according to information provided by the WHO and scientists involved in the testing.

The outbreak is concentrated in the northeastern DRC, with more than 97 percent of cases in Ituri, North Kivu and South Kivu provinces. The DRC has announced free healthcare for all illnesses in Ituri as the Ebola outbreak continues to gain ground.

Health officials anticipate that running trials and delivering care in the eastern DRC will be difficult due to challenges such as disease testing, contact tracing, supply chain disruptions, mistrust, and attacks on health workers.

How each outlet told it

AllAfrica as of Jun 24, 2026, 12:31 PM UTC

Framing: Experimental Ebola drugs shipped to DRC as outbreak worsens — Informative and objective

Facts Included:

Experimental Ebola drugs are being shipped to Democratic Republic of Congo
Over 1,000 cases and over 250 deaths reported
US Department of Health and Human Services providing doses of MBP134 for clinical trials
Trials of MBP134 and two antivirals developed by Gilead Sciences to begin in coming weeks
No approved vaccines or treatments exist for the Bundibugyo strain of Ebola

Read the source article →

RFI — English as of Jun 24, 2026, 11:01 AM UTC

Framing: Experimental Ebola drugs shipped to DRC as outbreak worsens — Informative and objective

Facts Included:

Experimental Ebola drugs are being shipped to Democratic Republic of Congo
Over 1,000 cases and over 250 deaths reported
US Department of Health and Human Services providing doses of MBP134 for clinical trials
Trials of MBP134 and two antivirals developed by Gilead Sciences to begin in coming weeks
No approved vaccines or treatments exist for the Bundibugyo strain of Ebola

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimExperimental Ebola drugs are being shipped to Democratic Republic of Congo as the United States releases doses of a treatment for clinical trials in a widening outbreak that has caused more than 1,000 cases and over 250 deaths.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimThe US Department of Health and Human Services will provide doses of MBP134, an antibody drug developed by California-based Mapp Biopharmaceutical, for compassionate use in the DRC and to support a clinical trial in the outbreak region.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimNo approved vaccines or treatments exist for the Bundibugyo strain of Ebola, which is responsible for the outbreak.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimThe DRC has recorded more than 1,000 confirmed cases since the outbreak was confirmed on 15 May.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimTrials of MBP134 and two antivirals developed by US pharmaceutical company Gilead Sciences are due to begin in the coming weeks.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimThe Ebola outbreak is concentrated in the northeastern DRC, with more than 97 percent of cases in Ituri, North Kivu and South Kivu provinces.	ConfidenceHigh	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim
ClaimRunning trials and delivering care in the eastern DRC will be difficult due to challenges such as disease testing, contact tracing, supply chain disruptions, mistrust, and attacks on health workers.	ConfidenceMedium	StatusMulti-source quoted from RFI — English as of Jun 24, 2026, 11:01 AM UTC the outlets behind this status were not recorded for this claim

Transparency & Audit Trail

2 outlets · 2 articles consulted: AllAfrica, RFI — English 7 claims extracted Version 1 Written 2026-08-14